entertainment -WSS

entertainment

author：knowledge 2025-10-02 23:48:20 - browse：123

parts of a dna helix fades while a segment stays solid — Adobe

Flagship Pioneering, the venture capital firm behind Moderna, on Tuesday unveiled a new biotech called Quotient Therapeutics that will have offices in Massachusetts and the United Kingdom.

Quotient, which was founded last year and had operated in stealth mode, wants to develop drugs that target illnesses caused by genetic changes that occur as people age. Those conditions include immune diseases, cancers, neurodegenerative illnesses, and cardiometabolic disorders, such as heart attacks, strokes and diabetes.

With an initial of $50 million from the venture firm Flagship Pioneering, Quotient will be located in Cambridge, Mass., and Cambridge, England. Most of the academic co-founders work in the UK city. Quotient is the first Flagship-backed biotech that will be based in both countries.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Humans aren't the only ones with an imagination. Rats have it too

focus

Wikipedia

WSS

After Optum profits sink, UnitedHealth makes changes

Key Senate panel to consider PBM, drug pricing reform package

Lung cancer screening guidelines updated for cigarette smokers

Maui wildfire now ranks as the fifth

Gene therapy’s promise and the high cost of hope

The health care issue Democrats can’t solve: hospital reform

Wikipedia

entertainment

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

DeepMind touts AlphaFold's new skills as protein folding AI models face off

How to save PrEP access — and even expand it

How to convince healthy people to buy insurance

ChatGPT in medicine: STAT answers readers' burning questions

Illumina slashes 2023 revenue projections yet again

ChatGPT in medicine: STAT answers readers' burning questions

Hospitals are dialing back on venture capital investing

How to save PrEP access — and even expand it

After Sarepta trial failure, Duchenne families brace for more debate

focus

Medicare must police algorithms in Medicare Advantage, Dems say

Medicare must police algorithms in Medicare Advantage, Dems say

Key Senate panel to consider PBM, drug pricing reform package

Novo Nordisk touts Wegovy study, but still struggling with supply

Kidney transplant patients stopped immunosuppressants in trial

Surge in Apellis stock fueled by confidence in safety of its eye drug

Wikipedia

focus

Wikipedia

focus